KINICITI

Kiniciti is a US-based investment platform committed to building partnerships that leverage value from the infrastructure of cell and gene therapy breakthroughs. With a $250 million commitment from Welsh, Carson, Anderson & Stowe (WCAS), Kiniciti invests in non-therapeutic companies supporting CGT innovation that have the potential to transform the CGT ecosystem and deliver the promise of CGT to patients. Kiniciti's advisory board includes two inaugural members, Denis Bedoret, PhD, and Andrew Knudten, and their board of directors includes Dr. Michelle Dipp. Kiniciti is focused on opportunities that leverage technology and capabilities to drive transformational change and ensure CGT is delivered to those in need. Through strategic partnerships, the company has secured more than $60 million in capital to date. Kiniciti stands out from other businesses in the same industry by being focused on the urgency and capability of CGT, and by having a commitment to delivering the promise of CGT to patients in need.